Host factors and consequence of chemotherapy in pediatric cancer patients

Pediatric Blood and Cancer

Volumn 51, Issue 3, 2008, Pages 320-326

  Johnson, L'Aurelle A ^a,b   Ross, Julie A ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ALL; Pediatric oncology; Pharmacology

Indexed keywords

CYCLOPHOSPHAMIDE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; FOLLOW UP; HUMAN; LONG TERM CARE; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHILD; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 48249148305     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21630     Document Type: Review

References (67)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statist Rev 1975-2005. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2005/
2. Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol 2004;125:421-434.
3. Kersun LS, Wimmer RS, Hoot AC, et al. Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer 2004;42:289-291.
4. Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol 2005;22:89-101.
5. Koshy M, Paulino AC, Mai WY, et al. Radiation-induced osteosarcomas in the pediatric population. Int J Radiat Oncol Biol Phys 2005;63:1169-1174.
6. Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62:548-555.
7. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 325:1330-1336.
8. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257-4264.
9. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007;297:1207-1215.
10. Bo J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism. Cancer 1999;86:1080-1086.
11. Goodman G, The Pharmacological Basis of Therapeutics, 10th edition. Hardman JG, Limbird LE, Gilman AG, editors. New York: McGraw-Hill; 2001.
12. Stewart CF, Hampton EM. Effect of maturation on drug disposition in pediatric patients. Clin Pharm 1987;6:548-564.
13. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet 1980;5:485-527.
14. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 2002;50:259-265.
15. Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 2002;66:185-200.
16. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996;15: 17-30.
17. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-2301.
18. Marsh S, Collie-Duguid ES, Li T. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999;58:310-312.
19. Marsh S, Ameyaw MM, Githang'a J, et al. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000;16:528.
20. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-197.
21. Robien K, Bigler J, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 2006;12:973-980.
22. Robien K, Schubert MM, Chay T, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:799-800.
23. Kumagai K, Hiyama K, Oyama T, et al. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
24. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359:1033-1034.
25. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-272.
26. Hu X, Pal A, Krzeminski J, et al. Specificities of human glutathione S-transferase isozymes toward anti-diol epoxides of methylchrysenes. Carcinogenesis 1998;19:1685-1689.
27. Stanulla M, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study. Blood 2000;95:1222-1228.
28. Takanashi M, Morimoto A, Yagi T, et al. mpact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 2003;88:1238-1244.
29. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002;100:67-71.
30. Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006;46:317-353.
31. Bomgaars L, McLeod HL. Pharmacogenetics and pediatric cancer. Cancer J 2005;11:314-323.
32. Carroll WL, Bhojwani D, Min DJ, et al. Pediatric acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2003;102-131.
33. Krajinovic M, Labuda D, Sinnett D. Childhood acute lymphoblastic leukemia: Genetic determinants of susceptibility and disease outcome. Rev Environ Health 2001;16:263-279.
34. Ferencz C, Neill CA, Boughman JA, et al. Congenital cardiovascular malformations associated with chromosome abnormalities: An epidemiologic study. J Pediatr 1989;114:79-86.
35. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: Clinical characteristics and treatment outcome in four consecutive BFM trials.Berlin-Frankfurt-Munster Group. Leukemia 1998;12:645-651.
36. Rajantie J, Siimes MA. Long-term prognosis of children with Down's syndrome and leukaemia: A 34-year nation-wide experience. J Intellect Disabil Res 2003;47:617-621.
37. Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987;111:606-612.
38. Wheeler K, Chessells JM, Bailey CC, et al. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X. Arch Dis Child 1996;74:101-107.
39. Peeters M, Poon A. Down syndrome and leukemia: Unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987;146:416-422.
40. Blatt J, Albo V, Prin W, et al. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia. Lancet 1986;2:914.
41. Ueland PM, Refsum H, Christensen B. Methotrexate sensitivity in Down's syndrome: A hypothesis. Cancer Chemother Pharmacol 1990;25:384-386.
42. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma 1996;21:359-368.
43. Taub JW, Matherly LH, Stout ML, et al. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. Blood 1996;87: 3395-3403.
44. Taub JW, Huang X, Ge Y, et al. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D- arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: A model of leukemia in Down syndrome. Cancer Res 2000;60:6421-6426.
45. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428-1434.
46. Pollock BH, DeBaun MR, Camitta BM, et al. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 2000;18:813-823.
47. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003;290:2001-2007.
48. Pui CH, Boyett JM, Hancock ML, et al. Outcome of treatment for childhood cancer in black as compared with white children. The St Jude Children's Research Hospital experience, 1962 through1992. 1995; JAMA 273:633-636.
49. Bhatia S, Sather HN, Heerema NA, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood 2002;100:1957-1964.
50. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-1707.
51. Hedley AA, Ogden CL, Johnson CL, et al. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-2850.
52. Troiano RP, Flegal KM. Overweight children and adolescents: Description, epidemiology, and demographics. Pediatrics 1998; 101:497-504.
53. Lobstein T, Baur L, Uauy R. IASO International Obesity TaskForce. Obesity in children and young people: A crisis in public health. Obes Rev 2004;5:4-104.
54. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord 1999;23:S2-S11.
55. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm 1987;6:706-714.
56. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet 1993;25:103-114.
57. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986;11:199-213.
58. Powis G, Reece P, Ahmann DL, et al. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol 1987;20:219-222.
59. Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. Arthritis Rheum 1985;28:1117-1121.
60. Abernethy DR, Greenblatt DJ, Divoll M, et al. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 1981;217:681-685.
61. Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991;49:536-549.
62. Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: Studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983;101:873-880.
63. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37:8-19.
64. Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol 2007;25: 2063-2069.
65. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005; 293:203-211.
66. Hijiya N, Panetta JC, Zhou Y, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 2006;108:3997-4002.
67. Baillargeon J, Langevin AM, Lewis M, et al. Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2006;28:575-578.